首页> 美国卫生研究院文献>Journal of Thoracic Disease >Emergence of linezolid resistance in a clinical Staphylococcus capitis isolate from Jiangsu Province of China in 2012
【2h】

Emergence of linezolid resistance in a clinical Staphylococcus capitis isolate from Jiangsu Province of China in 2012

机译:2012年中国江苏省临床葡萄球菌分离株对利奈唑胺的耐药性出现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Linezolid (LZD) is an important antimicrobial agent for the treatment of infections caused by Gram-positive organisms, including methicillin-resistant Staphylococci. And until now, LZD resistance in clinical is still rare. Here we reported the first case of LZD resistance Staphylococcus capitis in Jiangsu, China. This strain was isolated from a 92-year old female who received long-term and repeatedly antibiotics treatment because of recurrent pulmonary infections in August 2012. Isolated from blood, the Staphylococcus capitis showed a resistance to LZD with a minimal inhibitory concentration (MIC) of 64 µg/mL, and the followed gene detection showed that the isolates existed C2190T and C2561Y point mutations in the 23S rRNA. Moreover, the isolation was also found carrying the cfr gene.
机译:利奈唑胺(LZD)是一种重要的抗菌剂,可用于治疗革兰氏阳性生物(包括耐甲氧西林的葡萄球菌)引起的感染。直到现在,临床上对LZD的耐药性仍然很少。在这里,我们报道了中国江苏省首例LZD耐药葡萄球菌炎。该菌株是从92岁的女性中分离出来的,该女性由于肺部反复感染于2012年8月接受了长期反复抗生素治疗。葡萄球菌capitis分离自血液,对LZD表现出抗性,最低抑制浓度(MIC)为64 µg / mL,随后的基因检测表明,分离株在23S rRNA中存在C2190T和C2561Y点突变。此外,还发现分离物携带cfr基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号